Human CD5 Protein, Fc Tag (MALS verified)
分子別名(Synonym)
CD5,LEU1
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human CD5 Protein, Fc Tag (CD5-H5255) is expressed from human 293 cells (HEK293). It contains AA Leu 159 - Pro 372 (Accession # P06127-1).
Predicted N-terminus: Leu 159
蛋白結(jié)構(gòu)(Molecular Characterization)

This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 50.1 kDa. The protein migrates as 55-57 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method / rFC method.
純度(Purity)
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

背景介紹
T細(xì)胞表面糖蛋白CD5(亦稱淋巴細(xì)胞抗原T1/Leu-1及LEU1)經(jīng)LYN激酶催化酪氨酸殘基磷酸化后,可為PTPN6/SHP-1創(chuàng)建結(jié)合位點(diǎn)。該蛋白作為受體參與T細(xì)胞增殖調(diào)控,在B細(xì)胞不同發(fā)育階段及活化狀態(tài)均有表達(dá)。CD5是T細(xì)胞受體(TCR)與B細(xì)胞受體(BCR)信號(hào)通路的經(jīng)典負(fù)向調(diào)控因子。CD5陽(yáng)性細(xì)胞還可通過(guò)分泌IL-10等細(xì)胞因子抑制自身免疫反應(yīng)。不同B/T細(xì)胞亞群的發(fā)育分化、選擇過(guò)程及功能維持,或其優(yōu)先存活機(jī)制,可能直接或間接依賴于CD5及類CD5分子相關(guān)的特定聚糖結(jié)構(gòu)。
關(guān)鍵字: CD5;CD5蛋白;CD5重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。